Skip to main content
. 2012 Aug 14;107(6):956–960. doi: 10.1038/bjc.2012.353

Figure 2.

Figure 2

Box plot of sHER2 changes after four cycles of chemotherapy in trastuzumab- and lapatinib-treated patients. Patients in the trastuzumab group experienced mainly sHER2 decreases, whereas in the lapatinib group, a significant number of sHER2 increases was observed.